Lilly stops development on cancer drug after failed study
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
Warner relies on funds from the Indiana Family and Social Administration, but the FSSA recently decided to end that funding after numerous complaints against the company went unresolved.
Five of the six Hoosier firms that appear in the 2013 rankings slipped from their positions in last year’s list of the largest U.S. companies.
John Lechleiter has been suffering from a dilated aorta, Eli Lilly and Co. said Monday. Current CFO Derica Rice will take his place until later this summer.
Lilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials. But some of those workers may be rehired by the firm.
Major drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.’s plan to sell Viagra directly to consumers. The bold move blows up the drug industry’s distribution model.
A pharmacy that makes specialty medications is recalling nearly 100 compounded drugs after federal regulators found potential safety problems during an inspection.
Investors are gaining confidence in the ability of major drugmakers, including Eli Lilly and Co., to improve their pipelines of new products. The big pharma firms begin to report first-quarter earnings this week.
The pharmaceutical firm has $400 million in projects in the works for its facilities south of downtown. City officials have advanced its request for tax breaks to a public hearing and final consideration May 1.
Indianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to a new manufacturing plant and improvements to existing operations downtown.
Investor smiles about new experimental cancer drugs and an aggressive play for the animal health market in China turned to frowns after Lilly disclosed deep cuts to its U.S. sales force.
The Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for the loss of patent protection on two of its best-selling drugs.
Lawyers for a security company being sued in the theft of $60 million worth of pharmaceuticals from an Eli Lilly and Co. warehouse in Connecticut say there's no proof the thieves used a report it prepared about security weaknesses in the building.
The idea behind the program, which starts in September, is that doctors can no longer leave the business aspect of their jobs to the finance guys while maintaining their integrity as healers.
A federal lawsuit contends that thieves who broke into an Eli Lilly and Co. warehouse in Connecticut three years ago and stole more than $60 million worth of drugs obtained a copy of a report that revealed weaknesses in the building's security system.
The new investment will bring the plant’s total price tag to $320 million as the pharmaceutical giant seeks to increase production of insulin and related products.
Indiana’s laws requiring hospitals to release price information are woefully inadequate, according to a report by two health insurance reform groups. Indiana was among 29 states to receive an "F" grade.
Johnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
Eli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker Boehringer Ingelheim to the Food and Drug Administration.
A central Indiana REIT that went public in 2012 has agreed to buy 13 senior housing and care facilities in three states, growing its asset value by 50 percent.